Scarica l'app Stockscreener
2.65
5.02%
-0.14
Dopo l'orario di chiusura:
2.65
Precedente Chiudi:
$2.79
Aprire:
$2.82
Volume 24 ore:
885.43K
Relative Volume:
0.73
Capitalizzazione di mercato:
$150.98M
Reddito:
-
Utile/perdita netta:
$-82.44M
Rapporto P/E:
-1.4096
EPS:
-1.88
Flusso di cassa netto:
$-66.75M
1 W Prestazione:
-3.64%
1M Prestazione:
-33.92%
6M Prestazione:
+14.72%
1 anno Prestazione:
+3.52%
Intervallo 1D:
$2.65
$2.82
Intervallo di 1 settimana:
$2.605
$2.84
Portata 52W:
$1.195
$4.94
Black Diamond Therapeutics Inc Stock (BDTX) Company Profile
Nome
Black Diamond Therapeutics Inc
Settore
Industria
Telefono
617-417-5868
Indirizzo
ONE MAIN STREET, 14TH FLOOR, CAMBRIDGE, MA
Confronta BDTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BDTX
Black Diamond Therapeutics Inc
|
2.65 | 158.96M | 0 | -82.44M | -66.75M | -1.88 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Black Diamond Therapeutics Inc Stock (BDTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2025-11-18 | Ripresa | Piper Sandler | Overweight |
| 2025-10-16 | Ripresa | Stifel | Buy |
| 2025-09-04 | Iniziato | Guggenheim | Buy |
| 2025-07-01 | Ripresa | Raymond James | Outperform |
| 2024-07-31 | Iniziato | Raymond James | Outperform |
| 2023-07-14 | Iniziato | Piper Sandler | Overweight |
| 2023-06-30 | Aggiornamento | Stifel | Hold → Buy |
| 2023-06-28 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2023-06-27 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2022-03-29 | Downgrade | Wedbush | Outperform → Neutral |
| 2022-03-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2021-09-30 | Iniziato | Stifel | Hold |
| 2021-01-07 | Iniziato | Wedbush | Outperform |
| 2020-11-24 | Iniziato | Berenberg | Buy |
| 2020-05-04 | Iniziato | H.C. Wainwright | Buy |
| 2020-02-24 | Iniziato | Canaccord Genuity | Buy |
| 2020-02-24 | Iniziato | Cowen | Outperform |
| 2020-02-24 | Iniziato | JP Morgan | Overweight |
| 2020-02-24 | Iniziato | Jefferies | Buy |
Mostra tutto
Black Diamond Therapeutics Inc Borsa (BDTX) Ultime notizie
Black Diamond Therapeutics (BDTX) – Analysts’ Weekly Ratings Updates - Defense World
A strong week for data readouts: Clinical Report - BioCentury
Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Can Black Diamond Therapeutics (BDTX) Turn Silevertinib’s Dual-Cancer Ambition Into a Cohesive Strategy? - Yahoo Finance
Down 30.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Black Diamond (BDTX) - sharewise.com
Can Black Diamond Therapeutics Inc. stock continue upward trendGap Down & Long-Term Investment Growth Plans - Newser
Will Black Diamond Therapeutics Inc. stock attract more institutional investorsInsider Selling & Technical Pattern Based Buy Signals - Newser
Black Diamond Therapeutics (NASDAQ:BDTX) Stock Rating Lowered by Guggenheim - MarketBeat
Stifel reiterates Buy rating on Black Diamond Therapeutics stock at $8 - Investing.com Australia
Analyst Downgrades BDTX to Neutral from Buy | BDTX Stock News - GuruFocus
This PayPal Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Thursday - Benzinga
How Black Diamond Therapeutics Inc. stock reacts to oil pricesBond Market & Consistent Profit Trade Alerts - Newser
Black Diamond Therapeutics (NASDAQ:BDTX) Downgraded by Guggenheim to Neutral - Defense World
Black Diamond's Lung Cancer Drug Shows 60% Response Rate In Phase 2 Data - Sahm
Are Smart Investors Making the Right Decision? Black Diamond Therapeutics Inc (BDTX) - Setenews
US Stocks Mixed; Dollar Tree Posts Upbeat Earnings - Benzinga
Black Diamond Therapeutics announces preliminary Phase 2 data for Silevertinib in 1L NSCLC - marketscreener.com
Black Diamond Therapeutics (BDTX) Reveals Promising Phase 2 Tria - GuruFocus
Black Diamond Therapeutics Announces Preliminary Phase 2 - GlobeNewswire
Black Diamond to present Phase 2 silevertinib trial results By Investing.com - Investing.com Canada
Black Diamond to present Phase 2 silevertinib trial results - Investing.com India
Black Diamond Therapeutics to Host Webcast on Phase 2 Clinical Trial Results of Silevertinib on December 3, 2025 - Quiver Quantitative
Black Diamond Therapeutics to Host Webcast Presentation Highlighting Silevertinib Phase 2 Clinical Trial Results and Program Update - The Manila Times
Black Diamond Therapeutics to Host Webcast Presentation - GlobeNewswire
Black Diamond Therapeutics, Inc. (BDTX) -9.9% in Intraday Trading: Decline Amid Routine Activity - Stocks Telegraph
Is Black Diamond Therapeutics Inc a good long term investmentCandlestick Trading Patterns & Learn to Trade with Real-Time Feedback - earlytimes.in
Adversity is less terrifying than hope: Black Diamond Therapeutics Inc (BDTX) - Setenews
Aug Retail: Why Black Diamond Therapeutics Inc. stock could benefit from AI revolutionTrade Volume Report & Expert Curated Trade Ideas - moha.gov.vn
Black Diamond Therapeutics Inc. (BDTX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
What insider trading reveals about Black Diamond Therapeutics Inc. stockQuarterly Profit Review & Fast Exit and Entry Strategy Plans - newser.com
Black Diamond Therapeutics: Underappreciated Despite An Upcoming Key Readout (NASDAQ:BDTX) - Seeking Alpha
Will Black Diamond Therapeutics Inc. stock pay special dividends2025 Momentum Check & Reliable Intraday Trade Plans - newser.com
Black Diamond Therapeutics (NASDAQ:BDTX) Upgraded at Piper Sandler - Defense World
Can Black Diamond Therapeutics Inc. stock hit record highs againJuly 2025 Review & Comprehensive Market Scan Reports - newser.com
Will Black Diamond Therapeutics Inc. stock maintain momentum in 2025July 2025 Highlights & AI Based Buy/Sell Signal Reports - newser.com
Volume spikes in Black Diamond Therapeutics Inc. stock – what they meanQuarterly Growth Report & Expert Curated Trade Setups - newser.com
Piper Sandler Initiates Coverage on Black Diamond Therapeutics (NASDAQ:BDTX) - MarketBeat
How geopolitical tensions affect Black Diamond Therapeutics Inc. stockJuly 2025 Short Interest & AI Powered Market Entry Strategies - newser.com
Black Diamond Therapeutics Inc Azioni (BDTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.36%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):